Disease · MONDO_0004647
in situ carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. in situ carcinoma. Diseases, record MONDO_0004647. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004647
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- carcinoma in situ, carcinoma, in situ, malignant, epithelial tumor, in situ, malignant, intraepithelial carcinoma, non-invasive carcinoma, stage 0 disease
- Open Targets
Drugs17
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| BCG LIVE | CHEMBL2108020 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets | |
| BCG VACCINE | CHEMBL2108905 | Vaccine component | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| CRETOSTIMOGENE GRENADENOREPVEC | CHEMBL5095454 | Gene | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| MITOMYCIN | CHEMBL105 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CETRELIMAB | CHEMBL4298001 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| NADOFARAGENE FIRADENOVEC | CHEMBL3990041 | Gene | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| OPORTUZUMAB MONATOX | CHEMBL1743052 | Antibody drug conjugate | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 17
See all 17 drugsTargets34
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 4 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 inhibitor | Phase 1 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| EEF2 | Elongation factor 2 | 1 | Elongation factor 2 inhibitor | Phase 3 | https://conductscience.org/library/genes/1938 | Drugs and targets |
| EPCAM | Epithelial cell adhesion molecule | 1 | Epithelial cell adhesion molecule binding agent | Phase 3 | https://conductscience.org/library/genes/4072 | Drugs and targets |
| IFNA2 | Interferon alpha-2 | 1 | Interferon alpha-2 exogenous gene | Phase 3 | https://conductscience.org/library/genes/3440 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5424 | Drugs and targets |
| POLD2 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5425 | Drugs and targets |
| POLD3 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/10714 | Drugs and targets |
1 to 10 of 34
See all 34 targetsTrials23
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04165317 | A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer | Phase 3 | 1,068 | 2026-01-22 | Non-muscle Invasive Bladder Cancer | BCG VACCINE, SASANLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02773849 | ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | 157 | 2022-07-13 | Superficial Bladder Cancer | NADOFARAGENE FIRADENOVEC | Its record names the disease | ClinicalTrials.gov |
| NCT02449239 | Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG | Phase 3 | 133 | 2023-07-24 | Bladder Cancer | OPORTUZUMAB MONATOX | Its record names the disease | ClinicalTrials.gov |
| NCT00453336 | Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract | Phase 2 | 45 | 2013-10-18 | Head and Neck Cancer, Precancerous/Nonmalignant Condition | PORFIMER SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT00530088 | Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat | Not applicable | 30 | 2014-07-04 | Head and Neck Cancer | PORFIMER SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT03258593 | Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | Phase 1 | 15 | 2023-10-26 | Urinary Bladder Neoplasms | DURVALUMAB, OPORTUZUMAB MONATOX | Its record names the disease | ClinicalTrials.gov |
| NCT05714202 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) | Phase 3 | 1,135 | Bladder Cancer | CETRELIMAB, GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07000084 | Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy | Phase 3 | 330 | Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8 | GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06545955 | A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | 250 | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | DOCETAXEL, GEMCITABINE, NADOFARAGENE FIRADENOVEC, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04640623 | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | Phase 2 | 220 | Urinary Bladder Neoplasms | CETRELIMAB, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 23
See all 23 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg vs Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 12 of 12 | 3 of 3 | 15 | NCT03258593 |
Source Trial comparisons
Papers from its trials23
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004647
GET https://conductscience.org/api/diseases/v1/MONDO_0004647/targets?page=2